A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis

NCT03496974 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: Bermekimab Monoclonal Antibody 200 mg
DRUG: Bermekimab Monoclonal Antibody 400 mg

Sponsor

Janssen Research & Development, LLC